IPP Bureau
AiMeD welcomes Govt’s for assistance to medical devices clusters
By IPP Bureau - May 16, 2023
The Niti Aayog and the DoP had listed a few factors that were leading to a 10-15% disability factor to be globally competitive
Health Minister Mandaviya invites Japanese pharma companies to invest in India
By IPP Bureau - May 16, 2023
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
Mandaviya addresses the G7 Health Ministerial Meeting on health innovation
By IPP Bureau - May 16, 2023
The need is to focus on an enabling framework to bridge the digital divide across countries specifically amongst low-and-middle-income countries
Mandaviya addresses the G7 Ministerial Meeting on global health architecture
By IPP Bureau - May 16, 2023
Cautions against fragmented & siloed efforts in addressing the challenges faced by the world and underlined the need for collaborative efforts to ensure global health security
Kraiburg TPE is breaking the mold in Asia Pacific’s innovative medical devices
By IPP Bureau - May 15, 2023
To enhance housing and enclosure design and performance for the Asia Pacific medical devices market, Kraiburg TPE offers the Thermoplast H HC/AP and HC/AD1/AP series
Medico Remedies to foray into ointment manufacturing segment
By IPP Bureau - May 15, 2023
The facility will have a capacity to manufacture upto 3 million tubes monthly
Advanced Enzyme Technologies posts Q4 FY23 consolidated PAT up at Rs. 32.12 Cr
By IPP Bureau - May 15, 2023
The company has reported total income of Rs. 149.78 crores during the period ended March 31, 2023
Rainbow Children's Medicare to set up around 400 beds in Gurugram
By IPP Bureau - May 15, 2023
The addition of these two hospitals will provide increased access to specialized pediatric and perinatal care services in the geography
Briefs: Dr. Reddy's Laboratories and Max Healthcare Institute
By IPP Bureau - May 15, 2023
Dr. Reddy's Laboratories has been issued a Form 483 with four observations
Dr. Lal Path Labs posts Q4 FY23 consolidated PAT at Rs. 56.7 Cr
By IPP Bureau - May 13, 2023
Dr. Lal Path Labs has reported total income of Rs. 505.2 crores during the period ended March 31, 2023
Alembic Q4 FY23 consolidated PAT up at Rs. 48.25 Cr
By IPP Bureau - May 13, 2023
Alembic has reported total income of Rs. 39.15 crores during the period ended March 31, 2023
Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr
By IPP Bureau - May 13, 2023
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
USFDA approves Astellas' Veozah’ for treatment of vasomotor symptoms due to menopause
By IPP Bureau - May 13, 2023
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
Nippon Express Italia receives IATA CEIV Pharma Certification for Its Facility near Milan Malpensa Airport
By IPP Bureau - May 13, 2023
Milan is also an important hub for the distribution of pharmaceuticals to the rest of Europe
Sanofi India to demerge healthcare businesses
By IPP Bureau - May 12, 2023
This decision will accelerate growth for both its pharma & consumer healthcare businesses in India
